Escala Medical

Company Overview

Snapshot

Founded in December 2014 by Douglas Scherr and Roger Goldberg, Escala Medical operates with 11–50 employees. The company has secured $8.05 million across four funding rounds. In July 2025, Escala Medical completed a Series A funding round, co-financed by the European Innovation Council (EIC) Fund, to support the global expansion of its FDA-approved Mendit device.

Business overview

Escala Medical is a Health Tech & Life Sciences company developing a medical device for pelvic organ prolapse. The company's core product is a nonsurgical, incision-free, mesh-free repair device designed to treat women with pelvic organ prolapse. This transvaginal technology mirrors surgery-based repair by fixating the vaginal apex to the sacrospinous ligament, offering a safe, quick outpatient procedure. Escala Medical serves the healthcare industry, specifically targeting women's health and medical treatment & therapeutics.

Strategic signal

In July 2025, Escala Medical successfully completed a Series A funding round, co-financed by the European Innovation Council (EIC) Fund. This investment is critical for the company's immediate forward trajectory, enabling the global expansion of its FDA-approved Mendit device into the U.S., Europe, and Southeast Asia, and supporting further product enhancements. This signals strong investor confidence in Escala Medical's innovative solution for pelvic organ prolapse and its potential to capture a significant share of the $7 billion global POP treatment market.

Company Intelligence Q&A

What was a significant recent funding event for Escala Medical?

In July 2025, Escala Medical completed a Series A funding round, co-financed by the European Innovation Council (EIC) Fund. This funding is intended to support the global expansion of Escala's FDA-approved Mendit device.

When did Escala Medical receive a grant from the European Innovation Council?

In March 2023, Escala Medical was awarded a grant from the European Innovation Council. This funding was intended to support the company's operations expansion and help transform pelvic organ prolapse treatment globally.

When did Escala Medical receive FDA regulatory clearance for its pelvic organ prolapse repair device?

In April 2022, Escala Medical received regulatory clearance from the FDA for its first pelvic organ prolapse repair device. This clearance positioned the company to introduce the device in the US market.

What is Escala Medical's primary focus in medical device development?

Escala Medical is focused on developing a nonsurgical, incision-free, mesh-free repair device to treat women with pelvic organ prolapse. Their technology provides a transvaginal approach to fixate the vaginal apex to the sacrospinous ligament.

What was the outcome of Escala Medical's equity crowdfunding round?

In January 2019, Escala Medical secured equity crowdfunding from ExitValley. This round contributed to the company's total funding of $8.05 million.